Dermatitis, Atopic (ATOD)

Categories: Genetic diseases, Immune diseases, Neuronal diseases, Skin diseases

Aliases & Classifications for Dermatitis, Atopic

MalaCards integrated aliases for Dermatitis, Atopic:

Name: Dermatitis, Atopic 56 6 43 39 71
Atopic Dermatitis 12 74 25 36 15 32
Atopic Eczema 12 25 15 17
Dermatitis, Atopic, Susceptibility to, 1 56 29 13
Atopic Neurodermatitis 12
Dermatitis, Atopic 1 56
Allergic Dermatitis 12
Besnier's Prurigo 12
Dermatitis Atopic 54
Eczema, Atopic 56
Eczema 71
Atod 56



food intolerance
diagnosis requires 3 major features (a positive family history is also considered a major feature) and at least 3 minor features

autosomal dominant


dermatitis, atopic:
Inheritance autosomal dominant inheritance


Summaries for Dermatitis, Atopic

Genetics Home Reference : 25 Atopic dermatitis (also known as atopic eczema) is a disorder characterized by inflammation of the skin (dermatitis). The condition usually begins in early infancy, and it often disappears before adolescence. However, in some affected individuals the condition continues into adulthood; in others, it does not begin until adulthood. Hallmarks of atopic dermatitis include dry, itchy skin and red rashes that come and go. The rashes can occur on any part of the body, although the pattern tends to be different at different ages. In affected infants, the rashes commonly occur on the face, scalp, hands, and feet. In children, the rashes are usually found in the bend of the elbows and knees and on the front of the neck. In adolescents and adults, the rashes typically occur on the wrists, ankles, and eyelids in addition to the bend of the elbows and knees. Scratching the itchy skin can lead to oozing and crusting of the rashes and thickening and hardening (lichenification) of the skin. The itchiness can be so severe as to disturb sleep and impair a person's quality of life. The word "atopic" indicates an association with allergies. While atopic dermatitis is not always due to an allergic reaction, it is commonly associated with other allergic disorders: up to 60 percent of people with atopic dermatitis develop asthma or hay fever (allergic rhinitis) later in life, and up to 30 percent have food allergies. Atopic dermatitis is often the beginning of a series of allergic disorders, referred to as the "atopic march." Development of these disorders typically follows a pattern, beginning with atopic dermatitis, followed by food allergies, then hay fever, and finally asthma. However, not all individuals with atopic dermatitis will progress through the atopic march, and not all individuals with one allergic disease will develop others. Individuals with atopic dermatitis have an increased risk of developing other conditions related to inflammation, such as inflammatory bowel disease, rheumatoid arthritis, and hair loss caused by a malfunctioning immune reaction (alopecia areata). They also have an increased risk of having a behavioral or psychiatric disorder, such as attention-deficit/hyperactivity disorder (ADHD) or depression. In a particular subset of individuals with atopic dermatitis, the immune system is unable to protect the body from foreign invaders such as bacteria and fungi (which is known as immunodeficiency). These individuals are prone to recurrent infections. Most also have other allergic disorders, such as asthma, hay fever, and food allergies. Atopic dermatitis can also be a feature of separate disorders that have a number of signs and symptoms, which can include skin abnormalities and immunodeficiency. Some such disorders are Netherton syndrome; immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome; and severe dermatitis, multiple allergies, metabolic wasting (SAM) syndrome.

MalaCards based summary : Dermatitis, Atopic, also known as atopic dermatitis, is related to dermatitis, atopic, 3 and dermatitis, atopic, 8, and has symptoms including pruritus and exanthema. An important gene associated with Dermatitis, Atopic is FLG (Filaggrin), and among its related pathways/superpathways are Akt Signaling and Cytokine Signaling in Immune system. The drugs Clobetasol and Mineral oil have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and t cells, and related phenotypes are cataract and ichthyosis

Disease Ontology : 12 A dermatitis that is a chronically relapsing inflammatory allergic response located in the skin that causes itching and flaking.

OMIM : 56 Atopic dermatitis (ATOD), also known as eczema, is a common chronic pruritic inflammatory skin disease with a strong genetic component. Onset typically occurs during the first 2 years of life (review by Soderhall et al., 2007). (603165)

KEGG : 36 Atopic dermatitis (AD) is a relapsing chronic inflammatory skin disease characterized by eczematous skin lesions and intense pruritus. A genetic defect in the filaggrin (FLG) protein and/or environmental factors are thought to cause AD by disrupting the epidermis. This disruption, in turn, results in contact between immune cells in the dermis and antigens from the external environment leading to intense itching, scratching, and inflammation. Apart from FLG, recent genome-wide association studies (GWASs) have identified many susceptibility loci of atopic dermatitis with genome-wide significance.

Wikipedia : 74 Atopic dermatitis (AD), also known as atopic eczema, is a type of inflammation of the skin (dermatitis).... more...

Related Diseases for Dermatitis, Atopic

Diseases in the Dermatitis, Atopic family:

Dermatitis, Atopic, 2 Dermatitis, Atopic, 3
Dermatitis, Atopic, 4 Dermatitis, Atopic, 5
Dermatitis, Atopic, 6 Dermatitis, Atopic, 7
Dermatitis, Atopic, 8 Dermatitis, Atopic, 9

Diseases related to Dermatitis, Atopic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 828)
# Related Disease Score Top Affiliating Genes
1 dermatitis, atopic, 3 35.2 FLG ATOD3
2 dermatitis, atopic, 8 35.2 IL10 ATOD8
3 asthma 34.7 STAT1 RNASE3 MIR155 IL5 IL4 IL31
4 egg allergy 34.2 IL5 IL4 IL10 IGHE FLG
5 dermatitis 34.0 RNASE3 MIR155 IL5 IL4 IL31 IL13
6 skin disease 33.1 RNASE3 MIR155 IL5 IL4 IL31 IL13
7 rhinitis 32.7 RNASE3 IL5 IL4 IL13 IL10 IGHE
8 allergic rhinitis 32.7 RNASE3 IL5 IL4 IL13 IL10 IGHE
9 allergic conjunctivitis 32.6 RNASE3 IL5 IL4 IL13 IL10 IGHE
10 food allergy 32.5 RNASE3 IL5 IL4 IL13 IL10 IGHE
11 bronchitis 32.5 STAT1 RNASE3 IL5 IL4 IL13 IL10
12 alopecia areata 32.5 IL4 IL13 IL10 FLG
13 contact dermatitis 32.4 IL5 IL4 IL31 IL10 FLG CCL27
14 cutaneous t cell lymphoma 32.3 STAT1 IL5 IL4 CCL17
15 allergic hypersensitivity disease 32.3 RNASE3 IL5 IL4 IL13 IL10 IGHE
16 allergic contact dermatitis 32.2 IL5 IL4 IL31 IL10 FLG CCL27
17 hypereosinophilic syndrome 32.2 RNASE3 IL5 IL4 IL13 IL10 IGHE
18 ige responsiveness, atopic 32.2 RNASE3 IL5 IL4 IL13 IL10 IGHE
19 bullous pemphigoid 32.1 RNASE3 IL5 IL4 IL31 IL13 IGHE
20 chickenpox 32.1 STAT1 IL4 IL10
21 atopic keratoconjunctivitis 32.1 RNASE3 IL5 IL4 IGHE
22 urticaria 32.1 RNASE3 IL5 IL4 IL31 IL13 IGHE
23 celiac disease 1 32.0 IL5 IL4 IL13 IL10
24 otitis media 32.0 RNASE3 IL5 IL4 IL10 IGHE
25 respiratory failure 32.0 RNASE3 IL5 IL13 IL10 CCL17
26 respiratory allergy 32.0 RNASE3 IL5 IL4 IL13 IL10 IGHE
27 cow milk allergy 32.0 RNASE3 IL5 IL4 IL10
28 cellulitis 31.9 RNASE3 IL5 IL10
29 blepharoconjunctivitis 31.9 RNASE3 IL4 CMA1
30 latex allergy 31.9 RNASE3 IL5 IL4 IL13 IGHE FLG
31 bronchiolitis 31.9 RNASE3 IL5 IL4 IL13 IL10
32 peanut allergy 31.8 IL5 IL4 IL13 IL10 IGHE FLG
33 chronic conjunctivitis 31.8 RNASE3 IL5 IL4 IL13 IL10 IGHE
34 inflammatory bowel disease 31.8 STAT1 MIR155 IL5 IL4 IL13 IL10
35 schistosomiasis 31.8 RNASE3 IL5 IL4 IL13 IL10 IGHE
36 irritant dermatitis 31.7 IL4 IL31 FLG
37 dermatitis herpetiformis 31.7 IL5 IL4 IL31 IL10
38 psoriasis 31.7 MIR155 IL5 IL4 IL31 IL13 IL10
39 vernal keratoconjunctivitis 31.7 RNASE3 IL5 IL4 IL13 IGHE
40 mastocytosis 31.7 IL4 IL31 IL13
41 conjunctival disease 31.7 RNASE3 IL5 IL4 IL13 IL10
42 onchocerciasis 31.7 RNASE3 IL5 IL4 IL13 IGHE
43 parasitic helminthiasis infectious disease 31.7 RNASE3 IL5 IL4 IL13 IL10
44 proteasome-associated autoinflammatory syndrome 1 31.7 RNASE3 IL5 IL4 IL13 IL10
45 lung disease 31.7 RNASE3 IL5 IL4 IL13 IL10
46 collagen disease 31.7 IL4 IL13 IL10
47 pulmonary disease, chronic obstructive 31.6 RNASE3 IL5 IL4 IL13 IL10
48 aspergillosis 31.6 IL5 IL4 IL10 CCL17
49 pollen allergy 31.6 RNASE3 IL5 IL13
50 wheat allergy 31.6 IGHE FLG

Graphical network of the top 20 diseases related to Dermatitis, Atopic:

Diseases related to Dermatitis, Atopic

Symptoms & Phenotypes for Dermatitis, Atopic

Human phenotypes related to Dermatitis, Atopic:

31 (show all 18)
# Description HPO Frequency HPO Source Accession
1 cataract 31 HP:0000518
2 ichthyosis 31 HP:0008064
3 abnormality of metabolism/homeostasis 31 HP:0001939
4 pallor 31 HP:0000980
5 pruritus 31 HP:0000989
6 dry skin 31 HP:0000958
7 asthma 31 HP:0002099
8 conjunctivitis 31 HP:0000509
9 eczema 31 HP:0000964
10 keratoconus 31 HP:0000563
11 recurrent skin infections 31 HP:0001581
12 allergic rhinitis 31 HP:0003193
13 atopic dermatitis 31 HP:0001047
14 food intolerance 31 HP:0012537
15 infra-orbital fold 31 HP:0011232
16 facial erythema 31 HP:0001041
17 keratosis pilaris 31 HP:0032152
18 flexural lichenification 31 HP:0007453

Symptoms via clinical synopsis from OMIM:

Skin Nails Hair Skin:
facial erythema
keratosis pilaris
pruritus (major feature)
Head And Neck Nose:
allergic rhinitis

elevated ige

Head And Neck Eyes:
cataracts (anterior- subcapsular)
conjunctivitis (recurrent)
orbital darkening

Respiratory Airways:
bronchial asthma

Laboratory Abnormalities:
immediate (type i) skin test reactivity

Clinical features from OMIM:


UMLS symptoms related to Dermatitis, Atopic:

pruritus, exanthema

Drugs & Therapeutics for Dermatitis, Atopic

Drugs for Dermatitis, Atopic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 464)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Clobetasol Approved, Experimental, Investigational Phase 4 25122-46-7, 25122-41-2 32798 5311051
Mineral oil Approved, Vet_approved Phase 4 8042-47-5
Bacitracin Approved, Vet_approved Phase 4 1405-87-4 439542 10909430
Bronopol Approved Phase 4 52-51-7
5 Parthenolide Approved, Investigational Phase 4 20554-84-1
Glycerol Approved, Investigational Phase 4 56-81-5 753
Petrolatum Approved, Investigational Phase 4 8009-03-8
carbamide peroxide Approved Phase 4 124-43-6
Fluticasone Approved, Experimental Phase 4 90566-53-3 62924
Montelukast Approved Phase 4 158966-92-8 5281040
Fluocinonide Approved, Investigational Phase 4 356-12-7 9642
Levocetirizine Approved Phase 4 130018-77-8 1549000
Desoximetasone Approved Phase 4 382-67-2 5311067
mometasone furoate Approved, Investigational, Vet_approved Phase 4 83919-23-7
Diphenhydramine Approved, Investigational Phase 4 147-24-0, 58-73-1 3100
Promethazine Approved, Investigational Phase 4 60-87-7 4927
Mupirocin Approved, Investigational, Vet_approved Phase 4 12650-69-0 446596
Triclosan Approved, Investigational Phase 4 3380-34-5 5564
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
Doxepin Approved, Investigational Phase 4 1668-19-5 667477 667468
Glucosamine Approved, Investigational Phase 4 3416-24-8 439213
Loteprednol Approved, Experimental Phase 4 129260-79-3, 82034-46-6 444025 9865442
Tobramycin Approved, Investigational Phase 4 32986-56-4 5496 36294
Omalizumab Approved, Investigational Phase 4 242138-07-4
tannic acid Approved Phase 4 1401-55-4
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
Omeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6 4594
Dexamethasone Approved, Investigational, Vet_approved Phase 4 50-02-2 5743
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4 1177-87-3
Zinc Approved, Investigational Phase 4 7440-66-6 32051
Zinc oxide Approved Phase 4 1314-13-2
Coal tar Approved Phase 4 8007-45-2
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
36 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
Methylprednisolone aceponate Approved, Vet_approved Phase 4 86401-95-8
Ustekinumab Approved, Investigational Phase 4 815610-63-0
Bleomycin Approved, Investigational Phase 4 11056-06-7 5360373
41 Vedolizumab Approved Phase 4 943609-66-3
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
Alitretinoin Approved, Investigational Phase 4 5300-03-8 444795 449171
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
Salicylic acid Approved, Investigational, Vet_approved Phase 4 69-72-7 338
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 134070 5280453
Enoxolone Investigational Phase 4 471-53-4 18526330
Cortisone Experimental Phase 4 53-06-5 222786
Chitosan Experimental Phase 4 9012-76-4 71853

Interventional clinical trials:

(show top 50) (show all 1111)
# Name Status NCT ID Phase Drugs
1 Effect of Moisturizing Creams on Skin Barrier Function Unknown status NCT00771121 Phase 4 urea/lactic acid;Placebo
2 Efficacy of KAM2904 Face Cream and KAM3008 Body Lotion Treatment in Children With Atopic Dermatitis (AD) Unknown status NCT01781663 Phase 4
3 Bronchiolitis All-study, SE-Norway What is the Optimal Inhalation Treatment for Children 0-12 Months With Acute Bronchiolitis? Unknown status NCT00817466 Phase 4 Racemic adrenaline;Isotonic saline
4 A Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trials to Evaluate the Efficacy and Safety of Runzao Zhiyang Capsule in Treating Chronic Eczema Unknown status NCT02601222 Phase 4 Runzao zhiyang capsule;Runzaozhiyang capsule agent simulation;Urea cream
5 Clinical Evaluation of T.R.U.E. Test Panel 3.2 in Children and Adolescents (PREA II) Unknown status NCT01797562 Phase 4 T.R.U.E. Test Panel 3.2
6 The Randomized Controlled Clinical Trial of Kushen Injection Reducing Radiotherapy Related Adverse Reactions in Lung Cancer Unknown status NCT02346318 Phase 4 Compound Kushen Injection
7 Comparing Treatment Efficacy With High and Medium Dose of Fluticasone in Combination With Salmeterol in COPD Patients Unknown status NCT01657487 Phase 4 Fluticasone/Salmeterol high dose
8 Comparison of Efficacy of Glycerol, Two Topical Steroids, and a Topical Immune Modulator Against Experimentally Induced Skin Irritation Unknown status NCT00779792 Phase 4 clobetasol;triamcinolone acetonide;tacrolimus;glycerol;vehicle ointment (paraffin oil/soft white paraffin)
9 Efficacy of Systemic Glucocorticoid in the Treatment of Wheezing in Children Unknown status NCT00494624 Phase 4 prednisolone
10 Prednisolone vs. Ciclosporine in Severe Atopic Eczema Completed NCT00445081 Phase 4 Prednisolone;Ciclosporine A
11 A 3-Month Open Label, National, Quality of Life , and Safety Study With Pimecrolimus Cream, 1% in Children (Age 2-12 Years ) With Atopic Dermatitis Completed NCT00484003 Phase 4 Pimecrolimus cream 1%
12 A Multi-Center Study to Assess the Impact of Topical Corticosteroids on the Safety and Efficacy of Protopic Ointment in the Short-Term Treatment of Atopic Dermatitis and to Assess Protopic in the Long-term Management of Atopic Dermatitis Completed NCT00106496 Phase 4 Protopic;Corticosteroid;placebo
13 A Randomized, Investigator Blinded Study of Protopic (Tacrolimus) Ointment Vs. Elidel (Pimecrolimus) Cream in Patients With Atopic Dermatitis Completed NCT00666302 Phase 4 tacrolimus ointment;pimecrolimus cream
14 A Phase IV,Open Label Study of the Treatment of Children With Moderate to Severe Atopic Dermatitis (AD) Using Locobase® REPAIR as an Adjunctive to Standard Treatment Completed NCT00673725 Phase 4 Locobase® REPAIR
15 Non-comparative Open-label Study to Investigate the Efficacy, Safety and Systemic Exposure of Pimecrolimus in Adult and Pediatric Patients With Moderate to Severe Atopic Dermatitis Treated Topically for 8.5 Days With Pimecrolimus Cream 1% Under Occlusion Completed NCT00925730 Phase 4 Pimecrolimus
16 The Role of Anti-IgE (Omalizumab) in the Management of Severe Recalcitrant Paediatric Atopic Eczema Completed NCT02300701 Phase 4 Xolair;Placebo
17 Effects of Pimecrolimus Cream 1% on the Molecular and Cellular Profile of Adult Male Patients With Atopic Dermatitis Completed NCT00117377 Phase 4 Pimecrolimus;Placebo
18 Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis Completed NCT00150059 Phase 4 Pimecrolimus Cream 1%
19 Open Label Multicenter Study, 52 Weeks Duration, Using Pimecrolimus Cream 1% for the Long-term Treatment of Mild to Moderate Atopic Dermatitis in Pediatric Patients Within a Usual Clinical Setting Completed NCT00509990 Phase 4 Pimecrolimus
20 Control of Therapy With Elidel vs Placebo in Patients With Atopic Dermatitis Using Bioengineering Methods Completed NCT00180141 Phase 4 Elidel-Creme
21 A Randomized, Investigator Blinded Study of Protopic (Tacrolimus) Ointment Vs. Elidel (Pimecrolimus) Cream in Pediatric Patients With Moderate to Severe Atopic Dermatitis Completed NCT00666159 Phase 4 tacrolimus ointment;pimecrolimus cream
22 Measuring Adherence to Topical Therapy in Children With Atopic Dermatitis and the Impact of a Return Visit Completed NCT00654355 Phase 4 tacrolimus ointment
23 A Multicenter, 3-week, Randomized, Double-blind, Parallel-group, Vehicle-controlled Study to Evaluate the Efficacy and Safety of Pimecrolimus Cream 1% in Pediatric Patients With Mild to Moderate Atopic Dermatitis Completed NCT00510003 Phase 4 Pimecrolimus
24 An Exploratory 16 Week, Double Blind, Placebo-Controlled Single Center Mechanistic Study to Determine the Effect of Rhumab-E25 on Phenotype and Function of IgE Mediated Antigen Presentation by Dendritic Cells in Subjects With Atopic Dermatitis. Completed NCT00822783 Phase 4 Omalizumab;Placebo
25 A Multicenter, Randomized, Double-blind Clinical Study to Examine the Efficacy and Safety of Zarzenda in Comparison to Elidel in the Management of Mild to Moderate Atopic Dermatitis in Children and Adolescents Completed NCT00568412 Phase 4 Elidel
26 An Open-label Multicenter 12-month Long Term Study on Skin Reconstitution With Pimecrolimus Cream 1% in Adult Patients With Atopic Eczema and Corticosteroid Induced Skin Damage Completed NCT00367393 Phase 4 Pimecrolimus cream 1%
27 Pimecrolimus Cream 1% Plus Topical Corticosteroid in Patients (2-17 Years of Age) With Severe Atopic Dermatitis Completed NCT00121381 Phase 4 Pimecrolimus plus topical corticosteroid (TCS);Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)
28 A Randomized, Investigator Blinded Study of Protopic (Tacrolimus) Ointment Vs. Elidel (Pimecrolimus) Cream in Pediatric Patients With Mild Atopic Dermatitis Completed NCT00667160 Phase 4 tacrolimus ointment;pimecrolimus cream
29 Comparison of Pimecrolimus Cream 1% Twice-Daily to Once-Daily Dosing in the Management of Atopic Dermatitis in Pediatric Subjects Completed NCT00139581 Phase 4 Pimecrolimus;Pimecrolimus
30 Efficacy and Safety of Pimecrolimus Cream 1% in Patients (2 to 11 Years Old) With Mild to Moderate Facial Atopic Dermatitis Completed NCT00130364 Phase 4 Pimecrolimus;Placebo
31 Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) of Patients Intolerant to, or Dependant on, Topical Corticosteroids Completed NCT00121316 Phase 4 Pimecrolimus;Placebo
32 Comparative, Multicentre, Randomized, Double-blind Study to Assess the Efficacy of Tacrolimus 0.1% Ointment Versus Fluticasone 0.005% Ointment in Adult Patients Suffering From Moderate to Severe Atopic Dermatitis and Presenting With So-called 'Red Face' Lesions of the Head and Neck. Completed NCT00690105 Phase 4 tacrolimus 0.1%;fluticasone 0.005 %
33 Comparative, Multicentre, Randomised, Double-blind Study to Assess the Efficacy of Tacrolimus 0.03% Ointment Versus Fluticasone 0.005% Ointment in Children Aged 2 Years or Over Suffering From Moderate to Severe Atopic Dermatitis. Completed NCT00689832 Phase 4 Tacrolimus 0.03%;Fluticasone 0.005%
34 Quality of Life Study in Adults With Facial Eczema Completed NCT00120302 Phase 4 Pimecrolimus;Placebo
35 A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy of Montelukast (Singulair) in Participants Ages 1 - 8 Years Diagnosed With Atopic Dermatitis Induced by Food Allergens Completed NCT00557284 Phase 4 Montelukast;Placebo
36 A Multi-Center, Open-Label Study to Evaluate the Effect of ALTANA Inc's Cutivate (Fluticasone Propionate) Lotion 0.05% on the Hypothalmic Pituitary Adrenal (HPA) Axis in the Treatment of Atopic Dermatitis in a Pediatric Population Completed NCT00546000 Phase 4 Fluticasone propionate 0.05% lotion
37 An Open-Label Study Evaluating the Efficacy of Fluocinonide Cream 0.1% (Vanos) in Subjects With Atopic Dermatitis Completed NCT01049243 Phase 4 Fluocinonide Cream 0.1%
38 Interaction of Orally Administered Lactobacillus Rhamnosus GG With Skin and Gut Microbiota and Humoral Immunity in Infants With Atopic Dermatitis Completed NCT01148667 Phase 4
39 Prospective, Randomized, Investigator-Blind, Controlled, Pilot Study Comparing Effect of Epiceram™ Device vs Standard of Care Therapy of Mid-Strength Topical Steroid (Fluticasone Propionate 0.05%) in Treatment of Atopic Dermatitis in Pediatric Subjects Completed NCT00616538 Phase 4 Fluticasone Propionate 0.05%
40 Management of Pruritus With Xyzal in Atopic Dermatitis in a Randomized, Double-Blind, Placebo Controlled Study Completed NCT00884325 Phase 4 Levocetirizine dihydrochloride (Xyzal);placebo
41 Phase IV - Evaluation of Cetaphil Advanced Usage to Control Light to Moderate Atopic Dermatitis, in Attempt to Reduce the Necessity of Topic Corticoids Application Completed NCT01063218 Phase 4
42 A Randomized, Double-Blinded Study of Epiceram Versus Elidel in Pediatric Subjects With Mild to Moderate Atopic Dermatitis Completed NCT00460083 Phase 4 Elidel(R) (pimecrolimus 1%)
43 A Randomized, Investigator-Blind, Six-Week, Parallel Group, Multicenter Pilot Study to Compare the Safety and Efficacy of EpiCeram Skin Barrier Emulsion and Desonide Cream 0.05% in the Twice Daily Treatment of Pediatric Subjects With Moderate Atopic Dermatitis Completed NCT00828412 Phase 4 Desonide Cream 0.05%
44 Short Term Growth in Children With Atopic Dermatitis Completed NCT00236106 Phase 4 tacrolimus ointment 0.1%;mometasone furoate 0.1%
45 Pimecrolimus Cream 1% (Elidel®) and Medicated Device Cream (EletoneTM) in the Treatment and Maintenance of Atopic Dermatitis. Completed NCT01177566 Phase 4 pimecrolimus
46 Effect of Cetaphil® Restoraderm® Moisturizer on Very Dry Skin in Children With a Controlled Atopic Dermatitis:a Randomised, Parallel Group Study Completed NCT02589392 Phase 4
47 Efficacy of Desonide (Desonatetm) Gel 0.05% in Younger and Older Subjects With Atopic Dermatitis Completed NCT00690833 Phase 4 topical desonide hydrogel 0.05%
48 An Investigator Blinded, Randomized, Controlled Study Comparing the Efficacy and Cost-Effectiveness of Aquaphor Healing Ointment, Atopiclair Nonsteroidal Cream (MAS063DP) and EpiCeram Skin Barrier Emulsion in Children With Mild to Moderate Atopic Dermatitis Completed NCT01093469 Phase 4 Atopiclair Nonsteroidal Cream;EpiCeram
49 Effects of a Novel Formulation of Fluocinonide 0.1% Cream on Skin Barrier Function in Atopic Dermatitis Completed NCT00819507 Phase 4 Fluocinonide
50 Prospective Clinical Trial to Assess the Efficacy and Safety of EPOGAM 1000 in Patients With Atopic Dermatitis (Explorative Pilot Study) Completed NCT00878670 Phase 4 EPOGAM 1000

Search NIH Clinical Center for Dermatitis, Atopic

Inferred drug relations via UMLS 71 / NDF-RT 50 :

Betamethasone acetate
Betamethasone benzoate
betamethasone dipropionate
betamethasone sodium phosphate
Betamethasone valerate
Doxepin Hydrochloride
Fluocinolone Acetonide
Methdilazine hydrochloride
trimeprazine tartrate
Triprolidine Hydrochloride
Zinc Oxide

Cochrane evidence based reviews: dermatitis, atopic

Genetic Tests for Dermatitis, Atopic

Genetic tests related to Dermatitis, Atopic:

# Genetic test Affiliating Genes
1 Dermatitis, Atopic, Susceptibility to, 1 29

Anatomical Context for Dermatitis, Atopic

The Foundational Model of Anatomy Ontology organs/tissues related to Dermatitis, Atopic:


MalaCards organs/tissues related to Dermatitis, Atopic:

Skin, Testes, T Cells, Colon, Breast, Monocytes, Bone

Publications for Dermatitis, Atopic

Articles related to Dermatitis, Atopic:

(show top 50) (show all 19959)
# Title Authors PMID Year
A nonsynonymous substitution of cystatin A, a cysteine protease inhibitor of house dust mite protease, leads to decreased mRNA stability and shows a significant association with atopic dermatitis. 54 61 56
17441792 2007
A major susceptibility locus for atopic dermatitis maps to chromosome 3q21. 54 61 56
11101848 2000
Linkage of atopic dermatitis to chromosomes 4q22, 3p24 and 3q21. 61 56
19517137 2009
Atopic dermatitis. 61 56
18385500 2008
Variants in a novel epidermal collagen gene (COL29A1) are associated with atopic dermatitis. 61 56
17850181 2007
Susceptibility loci for atopic dermatitis on chromosomes 3, 13, 15, 17 and 18 in a Swedish population. 61 56
12045207 2002
Linkage and association to candidate regions in Swedish atopic dermatitis families. 61 56
11511916 2001
Genetic linkage of childhood atopic dermatitis to psoriasis susceptibility loci. 61 56
11279517 2001
Association and linkage of atopic dermatitis with chromosome 13q12-14 and 5q31-33 markers. 61 56
11069631 2000
MiR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4. 61 46
20673989 2010
Mosaic atopic eczema cured by autotransplantation? 56
9752825 1998
The prevalence of childhood atopic eczema in a general population. 56
8277028 1994
Aetiology of asthma: lessons from lung transplantation. 56
8098790 1993
Transfer of allergen-specific IgE-mediated hypersensitivity with allogeneic bone marrow transplantation. 56
3059190 1988
Changes in the reported prevalence of childhood eczema since the 1939-45 war. 56
6150286 1984
The lines of Blaschko: a review and reconsideration: Observations of the cause of certain unusual linear conditions of the skin. 56
788770 1976
Sphingosylphosphorylcholine down-regulates filaggrin gene transcription through NOX5-based NADPH oxidase and cyclooxygenase-2 in human keratinocytes. 54 61
20230798 2010
Genetic variants in thymic stromal lymphopoietin are associated with atopic dermatitis and eczema herpeticum. 54 61
20466416 2010
[Safety of azathioprine therapy adjusted to thiopurine methyltransferase activity in the treatment of infantile atopic dermatitis. Report on 7 cases]. 54 61
20525484 2010
Thymic stromal lymphopoietin receptor-mediated IL-6 and CC/CXC chemokines expression in human airway smooth muscle cells: role of MAPKs (ERK1/2, p38, and JNK) and STAT3 pathways. 54 61
20483734 2010
Definition and characterization of an inhibitor for interleukin-31. 54 61
20335179 2010
Impact of heat-inactivated Lactobacillus casei and Lactobacillus paracasei strains on cytokine responses in whole blood cell cultures of children with atopic dermatitis. 54 61
20526842 2010
Analysis of four prevalent filaggrin mutations (R501X, 2282del4, R2447X and S3247X) in Austrian and German patients with atopic dermatitis. 54 61
19874431 2010
Flaky tail mouse denotes human atopic dermatitis in the steady state and by topical application with Dermatophagoides pteronyssinus extract. 54 61
20304960 2010
Mitochondrial reactive oxygen species control T cell activation by regulating IL-2 and IL-4 expression: mechanism of ciprofloxacin-mediated immunosuppression. 54 61
20335530 2010
Sensing the outside world: TSLP regulates barrier immunity. 54 61
20300138 2010
The role of thymic stromal lymphopoietin in allergic inflammation and chronic obstructive pulmonary disease. 54 61
20143171 2010
[Atopic dermatitis - current insights into path physiology and management]. 54 61
20336617 2010
Effects of transmembrane and juxtamembrane domains on proliferative ability of TSLP receptor. 54 61
20096461 2010
Sustained exogenous expression of therapeutic levels of IFN-gamma ameliorates atopic dermatitis in NC/Nga mice via Th1 polarization. 54 61
20107184 2010
Increased serum thymic stromal lymphopoietin in children with atopic dermatitis. 54 61
20444170 2010
Association of single nucleotide polymorphisms in the IL-12 (IL-12A and B) and IL-12 receptor (IL-12Rbeta1 and beta2) genes and gene-gene interactions with atopic dermatitis in Koreans. 54 61
20060272 2010
Unique epitopes on C epsilon mX in IgE-B cell receptors are potentially applicable for targeting IgE-committed B cells. 54 61
20083663 2010
Genetics of allergic disease. 54 61
20176270 2010
Reduced IFN-gamma- and enhanced IL-4-producing CD4+ cord blood T cells are associated with a higher risk for atopic dermatitis during the first 2 yr of life. 54 61
19552791 2010
Thymic stromal lymphopoietin. 54 61
20146705 2010
Human defensins and LL-37 in mucosal immunity. 54 61
19808939 2010
Association of single nucleotide polymorphism of interleukin-18 with atopic dermatitis. 54 61
19453784 2010
Locus 1q21 Gene expression changes in atopic dermatitis skin lesions: deregulation of small proline-rich region 1A. 54 61
19672094 2010
Antimicrobial peptides present in mammalian skin and gut are multifunctional defence molecules. 54 61
20030614 2010
Increase effect of transforming growth factor on eotaxin production by normal cultured dermal fibroblasts stimulated with interleukin-4: inhibitory effect of suplatast tosilate on eotaxin production. 54 61
20136617 2010
What is really in control of skin immunity: lymphocytes, dendritic cells, or keratinocytes? facts and controversies. 54 61
20082953 2010
Novel CC chemokine receptor 4 antagonist RS-1154 inhibits ovalbumin-induced ear swelling in mice. 54 61
19818758 2009
Increased pachyonychia congenita severity in patients with concurrent keratin and filaggrin mutations. 54 61
19785597 2009
Inflammatory cytokine tumor necrosis factor-alpha enhances nerve growth factor production in human keratinocytes, HaCaT cells. 54 61
19942804 2009
AN-2728, a PDE4 inhibitor for the potential topical treatment of psoriasis and atopic dermatitis. 54 61
19876791 2009
Impaired TLR-2 expression and TLR-2-mediated cytokine secretion in macrophages from patients with atopic dermatitis. 54 61
19392987 2009
Brain-derived neurotrophic factor gene polymorphisms and serum levels in Chinese atopic dermatitis patients. 54 61
19522715 2009
[The influence of the total immunoglobulin E level concentration in serum on the results of atopy patch tests in adult patients with atopic dermatitis]. 54 61
19928660 2009
Role of the epidermal barrier in atopic dermatitis. 54 61
19682176 2009

Variations for Dermatitis, Atopic

ClinVar genetic disease variations for Dermatitis, Atopic:

6 (show all 12) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 STAT1 NM_007315.3(STAT1):c.821G>A (p.Arg274Gln)SNV Pathogenic 30085 rs387906760 2:191859910-191859910 2:190995184-190995184
2 46;XX;t(7;13)(p13;q34)dnTranslocation Pathogenic 267841
3 46;XY;t(2;17)(p25;q23)dnTranslocation Pathogenic 268017
4 FLG NM_002016.1(FLG):c.1501C>T (p.Arg501Ter)SNV Pathogenic/Likely pathogenic 16319 rs61816761 1:152285861-152285861 1:152313385-152313385
5 46;X;t(X;12)(p11.2;q24.33)dnTranslocation Likely pathogenic 267860
6 KCNJ11 NM_000525.3(KCNJ11):c.185C>G (p.Thr62Arg)SNV Likely pathogenic 373928 rs1057518775 11:17409454-17409454 11:17387907-17387907
7 CYP4F22 NM_173483.4(CYP4F22):c.1211T>C (p.Leu404Pro)SNV Uncertain significance 523566 rs1555730246 19:15658993-15658993 19:15548182-15548182
8 CYP4F22 NM_173483.4(CYP4F22):c.1544G>T (p.Arg515Leu)SNV Uncertain significance 523567 rs1425964436 19:15662230-15662230 19:15551419-15551419
9 XDH NM_000379.4(XDH):c.1172C>T (p.Pro391Leu)SNV Uncertain significance 598996 rs1558697792 2:31602803-31602803 2:31379937-31379937
10 46;XY;t(16;20)(q23.1;p11.22)Translocation Uncertain significance 267924
11 46;XY;t(1;4)(q32;q11)Translocation Uncertain significance 268019
12 XDH NM_000379.4(XDH):c.3647C>A (p.Pro1216His)SNV Uncertain significance 335760 rs143981573 2:31562482-31562482 2:31339616-31339616

Expression for Dermatitis, Atopic

Search GEO for disease gene expression data for Dermatitis, Atopic.

Pathways for Dermatitis, Atopic

Pathways related to Dermatitis, Atopic according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
Show member pathways
13.28 STAT1 IL5 IL4 IL13 IL10 CCL27
Show member pathways
13.23 STAT1 IL5 IL4 IL31 IL13 IL10
Show member pathways
12.71 STAT1 RNASE3 IL5 IL4 IL13 IL10
Show member pathways
12.48 STAT1 IL5 IL4 IL13 IL10
Show member pathways
12.2 IL5 IL4 IL13 CCL17
Show member pathways
12.17 STAT1 IL5 IL4 IL13 IL10
Show member pathways
12.14 STAT1 IL5 IL4 IL13 IL10
8 11.78 STAT1 IL4 IL13 IL10 IGHE
9 11.69 STAT1 IL5 IL4 IL13
10 11.66 IL5 IL4 IL13 IL10
11 11.59 IL4 IL13 IL10 CCL17
12 11.47 IL5 IL4 IL13 CMA1
13 11.42 IL4 IL13 IL10
14 11.19 IL5 IL4 IL13
15 11.15 IL5 IL4 IL10 IGHE CCL17
16 11.02 IL5 IL4 IL13 IL10
17 10.9 IL5 IL4 IL13 IL10 CCL27 CCL17
18 10.87 IL5 IL4 IL13 IL10
19 10.76 IL5 IL4 IL31 IL13 IL10 CCL17

GO Terms for Dermatitis, Atopic

Cellular components related to Dermatitis, Atopic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 RNASE3 IL5 IL4 IL31 IL13 IL10
2 extracellular space GO:0005615 9.32 RNASE3 MIR155 IL5 IL4 IL31 IL13

Biological processes related to Dermatitis, Atopic according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 defense response to bacterium GO:0042742 9.81 IGHE IL10 MIR155 RNASE3
2 positive regulation of B cell proliferation GO:0030890 9.54 IL13 IL4 IL5
3 dendritic cell differentiation GO:0097028 9.52 IL4 MIR155
4 negative regulation of endothelial cell apoptotic process GO:2000352 9.5 IL10 IL13 IL4
5 immune response GO:0006955 9.5 IL5 IL4 IL13 IL10 IGHE CCL27
6 negative regulation of tumor necrosis factor biosynthetic process GO:0042536 9.49 IL10 IL4
7 positive regulation of MHC class II biosynthetic process GO:0045348 9.48 IL10 IL4
8 negative regulation of interleukin-8 production GO:0032717 9.46 IL10 MIR155
9 type 2 immune response GO:0042092 9.43 IL10 IL4
10 regulation of isotype switching GO:0045191 9.4 IL10 IL4
11 positive regulation of macrophage activation GO:0043032 9.33 IL10 IL13 MIR155
12 negative regulation of complement-dependent cytotoxicity GO:1903660 9.26 IL13 IL4
13 cytokine-mediated signaling pathway GO:0019221 9.17 STAT1 IL5 IL4 IL31 IL13 IL10

Molecular functions related to Dermatitis, Atopic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine receptor binding GO:0005126 9.13 IL4 IL31 IL13
2 cytokine activity GO:0005125 9.1 IL5 IL4 IL31 IL13 IL10 CCL17

Sources for Dermatitis, Atopic

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....